GMP-Grade Exosome Upstream Fermentation & Culture
OverviewServicesSamplesAdvantagesApplicationsFAQs
Overview
Upstream fermentation and culture is the foundation of every GMP microbial exosome manufacturing program. It is here—in the bioreactor and the media formulation—that vesicle identity, yield, purity, and batch-to-batch consistency are first established. Deviations that originate upstream propagate irreversibly through purification, QC release, and final product performance, making upstream process design one of the most consequential technical decisions in the entire manufacturing workflow.
As a specialized sub-service of GMP-Grade Exosome Manufacturing, this page focuses specifically on the upstream lifecycle: master and working cell bank preparation under cGMP, animal-component-free and chemically defined medium development, scalable bioreactor process design, real-time in-process monitoring with process analytical technology, and validated harvest and primary clarification protocols. Our approach is purpose-built for bacterial and fungal hosts, with dedicated protocols for the distinct cell envelope architectures of Gram-negative, Gram-positive, and fungal chassis. Every upstream campaign is executed within a quality management system that meets ICH Q7 and relevant pharmacopoeial standards for active pharmaceutical ingredient (API) starting material manufacture. Contact us to discuss your GMP upstream fermentation requirements.
Figure 1. GMP-grade upstream fermentation and culture workflow for microbial exosome production, spanning cell bank preparation, media development, bioreactor process design, in-process monitoring, and harvest with primary clarification.
Services
Service Workflow
Our GMP upstream fermentation workflow spans the complete project lifecycle, beginning with client consultation and technical alignment, then progressing through cell banking, media development, GMP bioreactor fermentation, in-process monitoring, and harvest with primary clarification. Each stage is managed within a phase-appropriate quality system that scales documentation rigor with process maturity—from early feasibility discussions through validated GMP production campaigns.
Service Details
GMP Cell Bank Preparation & Characterization
We establish fully characterized master cell banks (MCB) and working cell banks (WCB) under cGMP conditions. Each bank undergoes identity confirmation, viability assessment, purity testing for adventitious agents, and genetic stability evaluation. All banking operations are conducted in controlled cleanroom environments with full batch documentation that supports IND/IMPD submissions.
Chemically Defined Media Development for GMP Manufacturing
We formulate animal-component-free, chemically defined media optimized for both biomass accumulation and vesicle secretion in your production strain. Our systematic approach screens carbon sources, nitrogen sources, trace elements, and stress modulators using design-of-experiments methodology. Chemically defined formulations eliminate the variability and regulatory risk associated with complex media components while providing consistent proteomic and lipidomic profiles across production batches.
GMP Bioreactor Fermentation & Process Development
We design and execute scalable fermentation processes from bench-top development through pilot-scale GMP production. Process development systematically optimizes dissolved oxygen, pH, temperature, agitation, and feeding strategy. Fed-batch and continuous culture modes are benchmarked against batch operation for vesicle yield. Each process is characterized for particle yield, size distribution, and cargo composition, with critical process parameters identified and control ranges defined for validation.
In-Process Monitoring & Process Analytical Technology
Every GMP fermentation campaign includes real-time monitoring of critical process parameters using process analytical technology (PAT). We track dissolved oxygen, pH, temperature, agitation rate, gas flow rates, and optical density continuously. Scheduled in-process sampling monitors substrate consumption, metabolite accumulation, vesicle concentration, and microbial purity. All data is captured in electronic batch records with full audit trail capability for regulatory inspection readiness.
Harvest, Primary Clarification & Bulk Intermediate Storage
We validate harvest timing and primary clarification for every production strain to maximize intact vesicle recovery. Continuous-flow centrifugation and depth filtration are characterized for cell removal efficiency, vesicle retention, and shear-induced degradation. Clarified harvest material is stabilized and stored as a defined bulk intermediate under controlled conditions, with hold-time studies establishing maximum processing windows that support flexible downstream scheduling without compromising product quality.
Service Specifications & QC Standards
Instrumentation & Capability
- Cell Banking: Controlled-rate freezing and vapor-phase cryogenic storage with continuous temperature monitoring, supported by full chain-of-identity documentation.
- Bioreactor Systems: Bench-top development and pilot-scale stirred-tank bioreactors with single-use and stainless-steel options, configured for dissolved oxygen, pH, temperature, and off-gas monitoring.
- Media Preparation: Dedicated media preparation suite with water-for-injection or equivalent water systems and sterile filtration capacity for chemically defined and complex media formulations.
- In-Process Analytics: Online biomass monitoring, automated aseptic sampling, nanoparticle tracking analysis for vesicle concentration, and chromatographic or spectroscopic methods for substrate and metabolite profiling.
- Harvest Equipment: Continuous-flow centrifugation with scalable bowl configurations, depth filtration systems, and sterile collection vessels for bulk intermediate storage.
- Data Management: Electronic batch recording with secure data backup, user access controls, and audit trail capability for regulatory inspection readiness.
- Quality Systems: Independent QA oversight, raw material qualification and vendor audit program, environmental monitoring, and equipment calibration and preventive maintenance programs.
Turnaround Time
| Project Type |
Timeline |
| Strain characterization and cell bank feasibility |
4–6 weeks |
| MCB and WCB preparation with full characterization |
8–12 weeks |
| Chemically defined medium development |
6–10 weeks |
| Fermentation process development (bench-top, 1 strain) |
8–12 weeks |
| Process scale-up and GMP pilot engineering run |
6–8 weeks |
| GMP production campaign (per batch, after process lock) |
2–4 weeks |
| Full upstream process package (cell bank through validated GMP batch) |
24–36 weeks |
| Expedited timeline |
Available on request; additional fees and schedule acceleration depend on project scope and resource availability |
Timelines may vary based on strain complexity, media development iterations, scale requirements, and regulatory documentation scope.
Deliverables
- Cell bank documentation package: MCB and WCB certificates of analysis, identity and purity testing reports, genetic stability data, and storage condition validation.
- Media development report: Chemically defined formulation composition, raw material qualification summary, media preparation SOP, and comparability data versus complex medium baseline.
- Fermentation process description: Optimized process parameters with defined control ranges, engineering characterization data across scales, and CPP identification rationale.
- GMP batch records: Executed master batch records, in-process monitoring data, deviation and investigation reports (if applicable), and batch disposition documentation.
- Harvest and bulk intermediate report: Clarification process validation, hold-time study data, bulk intermediate certificate of analysis, and stability-indicating parameters.
- Regulatory support package: Process validation documentation, facility and equipment qualification summaries, and quality system descriptions suitable for IND/IMPD Module 3.
Quality Control
- Cell bank QC: Identity confirmation by sequencing and mass-spectrometry-based profiling. Viability, purity, and genetic stability tested per lot.
- Raw materials: All media components sourced from qualified vendors with certificates of analysis. Animal-component-free and TSE/BSE-free certification for GMP-grade materials.
- In-process controls: Real-time monitoring of dissolved oxygen, pH, temperature, and agitation. Scheduled sampling for biomass, substrate/metabolite concentrations, vesicle count, and microbial purity.
- Harvest intermediate QC: Vesicle concentration, size distribution, protein content, appearance, pH, osmolality, and bioburden prior to release to downstream processing.
- Environmental monitoring: Active and passive air sampling, surface monitoring, and personnel monitoring per campaign in controlled manufacturing areas. Trending and alert/action limit programs in place.
- Data integrity: Electronic systems with unique user logins, electronic signatures, and immutable audit trails. Paper records maintained per ALCOA+ principles.
- Batch release: Independent QA review and disposition of every GMP batch against pre-defined specifications prior to release for downstream processing or client delivery.
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Production strain identity, source, and biosafety level
- Strain type (Gram-negative, Gram-positive, or fungal)
- Prior fermentation or growth characterization data
- Target vesicle yield or production scale
- Intended clinical application and regulatory filing territory
- Any known genetic modifications or engineering history
|
- Prior fermentation protocol or process development data
- Reference vesicle characterization data (NTA, TEM, DLS)
- Preferred medium type or known nutrient requirements
- Desired MCB vial count and storage format
- In-process or release specifications from prior campaigns
- Regulatory correspondence or agency feedback on upstream process
|
- High-containment pathogens beyond current facility capability
- Strains of unknown or undocumented origin
- Genetically modified organisms without complete modification history
- Cultures with confirmed or suspected contamination
- Strains producing known toxins without suitable detoxification strategy
- Samples shipped without cold-chain documentation and temperature loggers
|
Recommended Starting Material by Service:
| Service |
Minimum |
Recommended |
| Strain characterization and cell bank feasibility |
Glycerol stock or agar stab with strain documentation |
Multiple glycerol stocks from independent cultures |
| MCB preparation (GMP) |
Characterized isolate with documented passage history |
Research cell bank with sufficient vials for MCB expansion |
| Chemically defined medium development |
Strain able to grow on minimal or semi-defined medium |
Prior growth data on complex medium for benchmarking |
| Fermentation process development |
Production strain with preliminary growth data |
Prior shake-flask or small-scale bioreactor data |
| GMP pilot production campaign |
Characterized WCB vial(s) + locked fermentation process description |
Engineering run data confirming process at target scale |
Storage & Shipping: Ship production strains as glycerol stocks or agar stabs on dry ice with continuous temperature monitoring and chain-of-custody documentation. Include strain origin, isolation history, biosafety classification, and any relevant genetic modification details. For strains with special biosafety considerations, coordinate with our QA team in advance to establish handling, containment, and waste inactivation procedures aligned with your biosafety documentation. All client strains are handled under Material Transfer and Confidentiality Agreements with secure, access-controlled storage.
Our Advantages
- Microbial-Native Fermentation Expertise — Upstream processes are designed for bacterial and fungal hosts from the outset, accounting for cell-envelope architecture, vesicle biogenesis, and strain-specific nutrient requirements rather than adapting mammalian protocols.
- Chemically Defined Media by Default — We prioritize animal-component-free, chemically defined media from the earliest development stages to reduce batch variability and simplify regulatory review of raw material sourcing.
- Scalable Process Design — Fermentation processes are characterized across scales with defined critical process parameters and control ranges, supporting smooth transition from bench-top development to pilot-scale GMP production.
- Integrated PAT and Data Integrity — Real-time monitoring of critical parameters with full audit-trail capture ensures upstream campaigns are inspection-ready and support downstream specification setting.
- Upstream-to-Downstream Specification Continuity — Harvest intermediates are designed with downstream purification and QC requirements in mind, reducing hand-off losses and specification mismatches.
Applications
mEV Therapeutic Development
GMP-grade mEVs as active pharmaceutical ingredients for IND-enabling studies and clinical trials in oncology, inflammatory disease, and regenerative medicine.
OMV-Based Vaccine Manufacturing
GMP-compliant OMV production from engineered or wild-type bacterial strains for prophylactic and therapeutic vaccine development.
mEV Drug Delivery Systems
GMP-manufactured mEVs as nanocarriers for targeted delivery of nucleic acids, small molecules, and protein therapeutics.
BEV Reference Standards & Research Reagents
Well-characterized GMP-grade mEV batches as reference materials for assay development, instrument qualification, and inter-laboratory standardization.
FAQs
Q: What distinguishes GMP-grade upstream fermentation from research-grade fermentation?
A: GMP-grade upstream fermentation operates under a formal quality management system with independent QA oversight, qualified facilities and equipment, validated processes, defined raw material specifications, documented batch records, and full traceability from cell bank vial to harvest intermediate. Research-grade fermentation is more flexible and lower cost but lacks the documentation, traceability, and quality assurance infrastructure required for clinical trial material manufacture.
Q: Which microbial production strains can you support for GMP fermentation?
A: Our platform covers Gram-negative bacteria (E. coli, Pseudomonas, Salmonella derivatives), Gram-positive bacteria (Lactobacillus, Bacillus, Bifidobacterium, Staphylococcus), and fungal hosts (Saccharomyces cerevisiae, Pichia pastoris). Strains within our facility's biosafety containment capability are accepted. High-containment pathogens are not currently supported. If your strain falls outside these categories, contact us for a feasibility evaluation.
Q: Can you prepare MCB and WCB under GMP conditions?
A: Yes. We prepare master cell banks and working cell banks under cGMP in controlled cleanroom environments with full characterization including identity, viability, purity testing for adventitious agents, and genetic stability. The resulting documentation package is structured to support IND or IMPD submissions for cell substrate characterization.
Q: Do I need chemically defined medium for GMP manufacturing?
A: While not an absolute regulatory requirement, chemically defined, animal-component-free media are strongly recommended for GMP manufacturing of therapeutic products. They eliminate the variability, adventitious agent risk, and supply chain dependence associated with complex media components such as yeast extract and peptones. Our team can transition your strain from complex to chemically defined medium using design-of-experiments optimization to achieve comparable productivity while meeting GMP raw-material expectations.
Q: How is process scalability demonstrated across fermentation scales?
A: Scale-up is addressed through engineering characterization of mass transfer, mixing, and shear at each scale, with the goal of maintaining equivalent physiological conditions for the production strain. We generate comparability data for vesicle yield, size distribution, and cargo composition at development and pilot scales to demonstrate that critical quality attributes are maintained across scales. This data forms the basis of the process validation package for regulatory submission.
Q: Can you increase vesicle yield through genetic engineering of the production strain?
A: Yes. We offer hypervesiculating strain engineering as a complementary service through our strain engineering platform. Strategies include Tol-Pal system disruption, OmpA/Lpp linkage weakening, and metabolic network modifications. Engineered strains can be incorporated into the GMP cell banking and fermentation workflow with appropriate documentation of the genetic modification history and characterization of the engineered construct.
Q: What documentation will I receive for a GMP production campaign?
A: Each GMP campaign delivers a complete documentation package: executed master batch records with all in-process data, certificates of analysis for the harvest intermediate, deviation and investigation reports (if any), environmental monitoring summaries, equipment use logs, and a batch disposition statement from QA. For programs advancing toward clinical trials, we additionally provide facility qualification summaries, equipment IQ/OQ/PQ documentation, and quality system descriptions structured for Module 3 regulatory submission.
Q: Can I transition an existing research-grade fermentation process to GMP?
A: Yes. Our process tech-transfer workflow begins with a detailed review of your existing protocol, followed by a gap analysis against GMP requirements. We then execute a laboratory-scale confirmation run, develop the GMP batch record, and perform an engineering run at the target GMP scale to demonstrate process reproducibility before committing to the formal GMP campaign. This phased approach identifies and resolves potential issues before they impact a registered GMP batch, protecting both your timeline and your investment.
